Newcastle University Translational and Clinical Research Institute,
Faculty of Medical Sciences,
Newcastle University Translational and Clinical Research Institute, Faculty of Medical Sciences
Helen Reeves graduated from Nottingham Medical school in 1990, moving shortly afterwards to Newcastle-upon-Tyne under the mentorship of Professor Oliver James. She completed a PhD studying cell signaling pathways in liver fibrosis and then worked as a post-doctoral scientist with Professor Scott Friedman at Mount Sinai Medical School in New York, studying aspects of the molecular pathogenesis of cancers. Presently she is Professor of Liver Cancer in the Newcastle University Center for Cancer and is the clinical lead for the care of patients with hepatocellular carcinoma in North East England and Cumbria. She has been a scientific committee member for the British Association for Cancer Research and the European Association for Study of the Liver. She is an active member of the HCC-UK Committee. Her main research focus is on HCC in patients with NAFLD and in the development of clinically relevant biomarkers. She also has a keen interest in the promotion of education and training of young scientific investigators and clinical researchers. She has a program grant from CRUK centred on exploring the roles of neutrophils in liver cancer. She is also the PI for the Liver Cancer focused Accelerator award, jointly funded by CRUK, FC AECC and AIRC entitled ‘HUNTER: Hepatocellular Carcinoma Expediter Network’.
The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease.
Gastroenterology Jul, 2008 | Pubmed ID: 18515091
AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease.
BMC cancer Jul, 2008 | Pubmed ID: 18638391
A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease.
BMC cancer Aug, 2009 | Pubmed ID: 19656391
The role of tobacco-derived carcinogens in pancreas cancer.
ISRN oncology , 2011 | Pubmed ID: 22084727
Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease.
Hepatology (Baltimore, Md.) Apr, 2012 | Pubmed ID: 22095588
Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis.
Journal of hepatology May, 2013 | Pubmed ID: 23353867
Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team.
Journal of hepatology Jan, 2014 | Pubmed ID: 23978719
The rate of production of uric acid by hepatocytes is a sensitive index of compromised cell ATP homeostasis.
American journal of physiology. Endocrinology and metabolism Nov, 2013 | Pubmed ID: 24045866
The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology Jan, 2014 | Pubmed ID: 24220911
Reply to "Hepatocellular carcinoma and the Newcastle-upon-Tyne area".
Journal of hepatology Jun, 2014 | Pubmed ID: 24602766
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.
Nature communications Jun, 2014 | Pubmed ID: 24978903
DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.
Clinical cancer research : an official journal of the American Association for Cancer Research Feb, 2015 | Pubmed ID: 25480831
Reply to: HCC and liver disease risk in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance.
Journal of hepatology Apr, 2015 | Pubmed ID: 25559329
Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis.
Journal of hepatology Jun, 2015 | Pubmed ID: 25623824
Regioselective sulfamoylation at low temperature enables concise syntheses of putative small molecule inhibitors of sulfatases.
Organic & biomolecular chemistry May, 2015 | Pubmed ID: 25858034
Hepatocellular carcinoma: optimal staging impacts survival.
Gastroenterology Jun, 2015 | Pubmed ID: 25921373
High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers.
International journal of cancer Jan, 2016 | Pubmed ID: 26178530
Assessment of the Hong Kong Liver Cancer Staging System in Europe.
Liver international : official journal of the International Association for the Study of the Liver 06, 2016 | Pubmed ID: 26677809
Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD.
Digestive diseases and sciences May, 2016 | Pubmed ID: 26921078
Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?
Journal of hepatology 08, 2016 | Pubmed ID: 27132171
Combination PARP and HDAC inhibition as a therapeutic strategy targeting liver cancer stem cells?
Chinese clinical oncology Oct, 2016 | Pubmed ID: 27164859
Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma.
British journal of cancer 09, 2016 | Pubmed ID: 27560551
Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytes.
Diabetes, obesity & metabolism 08, 2017 | Pubmed ID: 28206714
Design and synthesis of biphenyl and biphenyl ether inhibitors of sulfatases.
Chemical science Apr, 2016 | Pubmed ID: 28660059
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals.
Scientific reports 07, 2017 | Pubmed ID: 28674415
Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease.
Cancer medicine Aug, 2017 | Pubmed ID: 28677271
Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?
British journal of cancer 01, 2018 | Pubmed ID: 29123264
NAFLD-which patients should have hepatocellular carcinoma surveillance?
Hepatobiliary surgery and nutrition Oct, 2017 | Pubmed ID: 29152488
The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury.
Nature communications 12, 2017 | Pubmed ID: 29233977
Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).
Histopathology Sep, 2018 | Pubmed ID: 29573451
Liquid biopsy for liver diseases.
Gut 12, 2018 | Pubmed ID: 30177542
Reply to 'Comment on 'Circulating Neutrophils in patients with hepatocellular carcinoma".
British journal of cancer 09, 2018 | Pubmed ID: 30206368
Fatty Liver Disease and Hepatocellular Carcinoma: The Pathologist's View.
Advances in experimental medicine and biology , 2018 | Pubmed ID: 30362090
Weighing the benefits of hepatocellular carcinoma surveillance against potential harms.
Journal of hepatocellular carcinoma , 2019 | Pubmed ID: 30666302
The CCR2 Macrophage Subset Promotes Pathogenic Angiogenesis for Tumor Vascularization in Fibrotic Livers.
Cellular and molecular gastroenterology and hepatology , 2019 | Pubmed ID: 30704985
Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
Scientific reports 03, 2019 | Pubmed ID: 30842500
From NASH to HCC: current concepts and future challenges.
Nature reviews. Gastroenterology & hepatology 07, 2019 | Pubmed ID: 31028350
Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy.
The Journal of clinical investigation 01, 2020 | Pubmed ID: 31581151
Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma.
Liver cancer Apr, 2020 | Pubmed ID: 32399431
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.
Journal of hepatology 04, 2021 | Pubmed ID: 33248170
High subcutaneous adipose tissue density correlates negatively with survival in patients with hepatocellular carcinoma.
Liver international : official journal of the International Association for the Study of the Liver 04, 2021 | Pubmed ID: 33280219
Treatment strategies for early stage hepatocellular carcinoma: a systematic review and network meta-analysis of randomised clinical trials.
HPB : the official journal of the International Hepato Pancreato Biliary Association Apr, 2021 | Pubmed ID: 33309569
Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians.
Hepatobiliary surgery and nutrition Jan, 2021 | Pubmed ID: 33575290
Neutrophils induce paracrine telomere dysfunction and senescence in ROS-dependent manner.
The EMBO journal May, 2021 | Pubmed ID: 33764576
A Role in the Genetic Predisposition to NAFLD-HCC?
Cancers Mar, 2021 | Pubmed ID: 33808740
NAFLD-Associated HCC: Progress and Opportunities.
Journal of hepatocellular carcinoma , 2021 | Pubmed ID: 33854987
Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.
Journal of hepatology Oct, 2021 | Pubmed ID: 33992698
Combined hepatocellular-cholangiocarcinoma - More questions than answers.
Liver international : official journal of the International Association for the Study of the Liver 06, 2021 | Pubmed ID: 34002474
Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity.
Cell death & disease 05, 2021 | Pubmed ID: 34050139
Key features of the environment promoting liver cancer in the absence of cirrhosis.
Scientific reports Aug, 2021 | Pubmed ID: 34408183
Cell-free DNA TAPS provides multimodal information for early cancer detection.
Science advances Sep, 2021 | Pubmed ID: 34516908
Marco Y. W. Zaki*,1,2,
Shishir Shetty*,2,
Alex L. Wilkinson2,
Daniel A. Patten2,
Fiona Oakley*,3,
Helen Reeves*,4,5
1Department of Biochemistry, Faculty of Pharmacy, Minia University,
2National Institute for Health Research Birmingham Liver Biomedical Research Unit and Centre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham,
3Newcastle Fibrosis Research Group, Biosciences Institute, Faculty of Medical Sciences, Newcastle University,
4Newcastle University Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University,
5The Liver Unit, Department of Medicine, Freeman Hospital, Newcastle-upon-Tyne Hospitals NHS Foundation Trust
关于 JoVE
版权所属 © 2024 MyJoVE 公司版权所有,本公司不涉及任何医疗业务和医疗服务。